Zhening Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhening Liu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chengfu Xu
Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
6 shared publications Hangkai Huang
Department of Gastroenterology, the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou 310003 China
2 shared publications- Hangkai Huang
Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
2 shared publications - Jinghua Wang
Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications - Shenghui Chen
Department of Gastroenterology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Zhejiang, China
2 shared publications Jiarong Xie
Department of Gastroenterology, the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou 310003 China
1 shared publication
Latest Publications
- Open Access
- 30 December 2023
- Published by Wiley in Portal Hypertension & Cirrhosis
- Vol. 2 (4) , 157-164
Global burden trends of MAFLD‐related liver cancer from 1990 to 2019
Aims: Metabolic dysfunction‐associated fatty liver disease (MAFLD) has become a serious public health challenge and is a cause of liver cancer. Reports on the global epidemiology of MAFLD‐related liver cancer remain limited. This study aimed to estimate the global burden trends of MAFLD‐related liver cancer between 1990 and 2019.Methods: We estimated the numbers of global incident cases, deaths, and disability‐adjusted life years (DALYs) of MAFLD‐related liver cancer by analyzing data from the Global Burden of Disease Study 2019. We also analyzed the trends and regional and national differentials of MAFLD‐related liver cancer. Finally, we investigated the influential factors for the trends in MAFLD‐related liver cancer.Results: Globally, there were 36,340 (95% uncertainty interval [UI]: 29,490–44,860) incident cases, 34,730 (95% UI: 28,390–43,180) deaths, and 795,810 (95% UI: 657,290–975,790) DALYs of MAFLD‐related liver cancer in 2019, representing increases of 205%, 195%, and 166% compared with 1990, respectively. The age‐standardized incidence, mortality, and DALY rates per 100,000 population in 2019 were 0.44, 0.43, and 9.64, respectively. The most pronounced increases in incidence, deaths, and DALYs were consistently observed in countries with a high sociodemographic index. Increasing trends were noted in these three measures since 2005, and the trends were much greater in men than in women.Conclusions: MAFLD‐related liver cancer poses a substantial global burden that continues to grow. Undesirable trends were observed in countries with a high sociodemographic index.
- 30 December 2023
- Published by Wiley in Portal Hypertension & Cirrhosis
- Vol. 2 (4) , 157-164
Open AccessGlobal burden trends of MAFLD‐related liver cancer from 1990 to 2019
Aims: Metabolic dysfunction‐associated fatty liver disease (MAFLD) has become a serious public health challenge and is a cause of liver cancer. Reports on the global epidemiology of MAFLD‐related liver cancer remain limited. This study aimed to estimate the global burden trends of MAFLD‐related liver cancer between 1990 and 2019.Methods: We estimated the numbers of global incident cases, deaths, and disability‐adjusted life years (DALYs) of MAFLD‐related liver cancer by analyzing data from the Global Burden of Disease Study 2019. We also analyzed the trends and regional and national differentials of MAFLD‐related liver cancer. Finally, we investigated the influential factors for the trends in MAFLD‐related liver cancer.Results: Globally, there were 36,340 (95% uncertainty interval [UI]: 29,490–44,860) incident cases, 34,730 (95% UI: 28,390–43,180) deaths, and 795,810 (95% UI: 657,290–975,790) DALYs of MAFLD‐related liver cancer in 2019, representing increases of 205%, 195%, and 166% compared with 1990, respectively. The age‐standardized incidence, mortality, and DALY rates per 100,000 population in 2019 were 0.44, 0.43, and 9.64, respectively. The most pronounced increases in incidence, deaths, and DALYs were consistently observed in countries with a high sociodemographic index. Increasing trends were noted in these three measures since 2005, and the trends were much greater in men than in women.Conclusions: MAFLD‐related liver cancer poses a substantial global burden that continues to grow. Undesirable trends were observed in countries with a high sociodemographic index.
- 29 March 2023
- Published by Wiley in Liver International
- Vol. 43 (5) , 1046-1055
Associations of serum uric acid levels with liver disease‐related morbidity and mortality: A prospective cohort study of the UK Biobank
Background and AimsThe association of serum uric acid (SUA) levels with liver-related morbidity and mortality remains undetermined. Therefore, we aimed to explore the association of SUA levels with liver-related morbidity and mortality. MethodsThe present cohort study included 459 619 adults from the UK Biobank. Multivariable Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations of SUA levels with morbidity and mortality of overall liver disease. Mendelian randomization (MR) analyses were conducted to explore the underlying causality. A polygenic risk score was generated to assess whether there was a gene-exposure interaction. ResultsDuring a median follow-up of 12.6 years, 14 302 nonfatal and 609 fatal cases of overall liver disease were identified. Compared to individuals in the lowest quartile, the HRs (95% CI) of incident overall liver disease were 1.08 (1.02-1.14), 1.13 (1.07-1.20) and 1.44 (1.36-1.53) for individuals with SUA levels in quartiles 2, 3 and 4 respectively. Similarly, the HRs (95% CI) of liver disease-associated mortality were 1.09 (0.78-1.52), 1.55 (1.14-2.13) and 1.96 (1.42-2.69) for individuals with SUA levels in quartiles 2, 3 and 4 respectively. The MR results did not support the causal association of SUA levels with liver disease. In addition, there was a significant modification effect of the polygenic risk score on the association of SUA levels with incident overall liver disease (p(interaction) = .003). ConclusionsHigher SUA levels were significantly associated with an increased risk of overall liver disease morbidity and mortality.
- 29 March 2023
- Published by Wiley in Liver International
- Vol. 43 (5) , 1046-1055
Associations of serum uric acid levels with liver disease‐related morbidity and mortality: A prospective cohort study of the UK Biobank
Background and AimsThe association of serum uric acid (SUA) levels with liver-related morbidity and mortality remains undetermined. Therefore, we aimed to explore the association of SUA levels with liver-related morbidity and mortality. MethodsThe present cohort study included 459 619 adults from the UK Biobank. Multivariable Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations of SUA levels with morbidity and mortality of overall liver disease. Mendelian randomization (MR) analyses were conducted to explore the underlying causality. A polygenic risk score was generated to assess whether there was a gene-exposure interaction. ResultsDuring a median follow-up of 12.6 years, 14 302 nonfatal and 609 fatal cases of overall liver disease were identified. Compared to individuals in the lowest quartile, the HRs (95% CI) of incident overall liver disease were 1.08 (1.02-1.14), 1.13 (1.07-1.20) and 1.44 (1.36-1.53) for individuals with SUA levels in quartiles 2, 3 and 4 respectively. Similarly, the HRs (95% CI) of liver disease-associated mortality were 1.09 (0.78-1.52), 1.55 (1.14-2.13) and 1.96 (1.42-2.69) for individuals with SUA levels in quartiles 2, 3 and 4 respectively. The MR results did not support the causal association of SUA levels with liver disease. In addition, there was a significant modification effect of the polygenic risk score on the association of SUA levels with incident overall liver disease (p(interaction) = .003). ConclusionsHigher SUA levels were significantly associated with an increased risk of overall liver disease morbidity and mortality.
- Open Access
Dietary Patterns and Long-Term Outcomes in Patients with NAFLD: A Prospective Analysis of 128,695 UK Biobank Participants
Large longitudinal studies exploring the role of dietary patterns in the assessment of long-term outcomes of NAFLD are still lacking. We conducted a prospective analysis of 128,695 UK Biobank participants. Cox proportional hazards models were used to estimate the risk associated with two dietary patterns for long-term outcomes of NAFLD. During a median follow-up of 12.5 years, 1925 cases of end-stage liver disease (ESLD) and 12,466 deaths occurred in patients with NAFLD. Compared with patients in the lowest quintile, those in the highest quintile of the diet quality score was negatively associated with the risks of ESLD and all-cause mortality (HRQ5vsQ1: 0.76, 95% CI: 0.66–0.87, p < 0.001; HRQ5vsQ1: 0.84, 95% CI: 0.79–0.88, p < 0.001, respectively). NAFLD patients with high-quality carbohydrate patterns carried a 0.74-fold risk of ESLD and a 0.86-fold risk of all-cause mortality (HRQ5vsQ1: 0.74, 95% CI: 0.65–0.86, p < 0.001; HRQ5vsQ1: 0.86, 95% CI: 0.82–0.91, p < 0.001, respectively). For prudent dietary patterns rich in vegetables, fruits and fish, the adjusted HR Q5vsQ1 (95% CI) was 0.87 (0.76–0.99) and 0.94 (0.89–0.99) for ESLD and all-cause mortality of NAFLD patients. There was a U-shaped association between the meat-rich dietary pattern and all-cause mortality in patients with NAFLD. These findings suggest that a diet characterized by a high-quality, high intake of vegetables, fruits, fish and whole grains as well as an appropriate intake of meat, was associated with a lower risk of adverse outcomes of NAFLD.
Open AccessDietary Patterns and Long-Term Outcomes in Patients with NAFLD: A Prospective Analysis of 128,695 UK Biobank Participants
Large longitudinal studies exploring the role of dietary patterns in the assessment of long-term outcomes of NAFLD are still lacking. We conducted a prospective analysis of 128,695 UK Biobank participants. Cox proportional hazards models were used to estimate the risk associated with two dietary patterns for long-term outcomes of NAFLD. During a median follow-up of 12.5 years, 1925 cases of end-stage liver disease (ESLD) and 12,466 deaths occurred in patients with NAFLD. Compared with patients in the lowest quintile, those in the highest quintile of the diet quality score was negatively associated with the risks of ESLD and all-cause mortality (HRQ5vsQ1: 0.76, 95% CI: 0.66–0.87, p < 0.001; HRQ5vsQ1: 0.84, 95% CI: 0.79–0.88, p < 0.001, respectively). NAFLD patients with high-quality carbohydrate patterns carried a 0.74-fold risk of ESLD and a 0.86-fold risk of all-cause mortality (HRQ5vsQ1: 0.74, 95% CI: 0.65–0.86, p < 0.001; HRQ5vsQ1: 0.86, 95% CI: 0.82–0.91, p < 0.001, respectively). For prudent dietary patterns rich in vegetables, fruits and fish, the adjusted HR Q5vsQ1 (95% CI) was 0.87 (0.76–0.99) and 0.94 (0.89–0.99) for ESLD and all-cause mortality of NAFLD patients. There was a U-shaped association between the meat-rich dietary pattern and all-cause mortality in patients with NAFLD. These findings suggest that a diet characterized by a high-quality, high intake of vegetables, fruits, fish and whole grains as well as an appropriate intake of meat, was associated with a lower risk of adverse outcomes of NAFLD.
- Open Access
- 16 December 2022
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 130 (6) , 996-1004
Association between ultra-processed foods consumption and risk of non-alcoholic fatty liver disease: a population-based analysis of NHANES 2011–2018
An increasing number of studies have evaluated the association between ultra-processed foods (UPF) consumption and metabolic disorders. However, the association between UPF intake and non-alcoholic fatty liver disease (NAFLD) remains unclear. In this study, we analysed data from 6545 participants who were recruited in National Health and Nutrition Examination Surveys 2011–2018. UPF were defined in light of the NOVA food classification system and divided into quartiles based on its proportion of total weight intake. Complex logistic regression models were used to assess the association between UPF and NAFLD. Mediation analyses were conducted to reveal underlying mediators. We found that NAFLD patients consumed more UPF than controls (925·92 ± 18·08v. 812·70 ± 14·32 g/d,P< 0·001). Dietary intake of UPF (% weight) was negatively related to the Healthy Eating Index-2015 score (Spearmanr= −0·32,P< 0·001). In the multivariable model, the highest quartile compared with the lowest, the OR (95 % CI) were 1·83 (1·33, 2·53) for NAFLD (OR per 10 % increment: 1·15; 95 % CI: 1·09, 1·22;Pfor trend < 0·001) and 1·52 (1·12, 2·07) for insulin resistance (OR per 10 % increment: 1·11; 95 % CI: 1·05, 1·18;Pfor trend = 0·002). Mediation analyses revealed that poor diet quality, high saturated fat and refined grain intake partly mediated the association between UPF and NAFLD. In conclusion, high UPF intake was associated with an increased risk of NAFLD in US adults. Further prospective studies are needed to verify these findings.
- 16 December 2022
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 130 (6) , 996-1004
Open AccessAssociation between ultra-processed foods consumption and risk of non-alcoholic fatty liver disease: a population-based analysis of NHANES 2011–2018
An increasing number of studies have evaluated the association between ultra-processed foods (UPF) consumption and metabolic disorders. However, the association between UPF intake and non-alcoholic fatty liver disease (NAFLD) remains unclear. In this study, we analysed data from 6545 participants who were recruited in National Health and Nutrition Examination Surveys 2011–2018. UPF were defined in light of the NOVA food classification system and divided into quartiles based on its proportion of total weight intake. Complex logistic regression models were used to assess the association between UPF and NAFLD. Mediation analyses were conducted to reveal underlying mediators. We found that NAFLD patients consumed more UPF than controls (925·92 ± 18·08v. 812·70 ± 14·32 g/d,P< 0·001). Dietary intake of UPF (% weight) was negatively related to the Healthy Eating Index-2015 score (Spearmanr= −0·32,P< 0·001). In the multivariable model, the highest quartile compared with the lowest, the OR (95 % CI) were 1·83 (1·33, 2·53) for NAFLD (OR per 10 % increment: 1·15; 95 % CI: 1·09, 1·22;Pfor trend < 0·001) and 1·52 (1·12, 2·07) for insulin resistance (OR per 10 % increment: 1·11; 95 % CI: 1·05, 1·18;Pfor trend = 0·002). Mediation analyses revealed that poor diet quality, high saturated fat and refined grain intake partly mediated the association between UPF and NAFLD. In conclusion, high UPF intake was associated with an increased risk of NAFLD in US adults. Further prospective studies are needed to verify these findings.
- Open Access
- 28 June 2022
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2022, 1-8
Association Between Serum Afamin Levels with Nonalcoholic Associated Fatty Liver Disease
Afamin is a member of the hepatokine that are strongly associated with various metabolic diseases. The relationship between afamin and nonalcoholic fatty liver disease (NAFLD) remains unclear. This study aimed to explore the correlation between serum afamin levels and NAFLD. We analyzed 88 NAFLD patients and 88 age- and sex-matched healthy controls who took their health examinations at the First Affiliated Hospital, Zhejiang University School of Medicine. The association was further confirmed in 22 biopsy-confirmed NAFLD patients and 36 healthy controls. Serum afamin levels were evaluated using an enzyme-linked immunosorbent assay (ELISA). NAFLD patients had significantly higher serum afamin levels than the healthy controls (14.79 ± 5.04 mg/L versus 10.83 ± 3.24 mg/L; ). Serum afamin levels were positively correlated with metabolic parameters including the body mass index, waist circumference, systolic blood pressure, liver enzymes, and lipid profiles. A multiple regression analysis showed that serum afamin levels were independently related to the risk of NAFLD (OR: 1.289, 95% CI, 1.141–1.456; ). The receiver operating characteristic (ROC) analysis showed that the area under curve (AUC) of serum afamin plus the BMI for detecting NAFLD was 0.878. In participants with liver biopsies, the serum afamin plus the BMI detected NAFLD with an AUC of 0.758. In conclusion, serum afamin levels were positively associated with prevalence and risk of NAFLD, and serum afamin plus the BMI had a high diagnostic performance for NAFLD. This study provides epidemiological evidence of afamin in NAFLD.
- 28 June 2022
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2022, 1-8
Open AccessAssociation Between Serum Afamin Levels with Nonalcoholic Associated Fatty Liver Disease
Afamin is a member of the hepatokine that are strongly associated with various metabolic diseases. The relationship between afamin and nonalcoholic fatty liver disease (NAFLD) remains unclear. This study aimed to explore the correlation between serum afamin levels and NAFLD. We analyzed 88 NAFLD patients and 88 age- and sex-matched healthy controls who took their health examinations at the First Affiliated Hospital, Zhejiang University School of Medicine. The association was further confirmed in 22 biopsy-confirmed NAFLD patients and 36 healthy controls. Serum afamin levels were evaluated using an enzyme-linked immunosorbent assay (ELISA). NAFLD patients had significantly higher serum afamin levels than the healthy controls (14.79 ± 5.04 mg/L versus 10.83 ± 3.24 mg/L; ). Serum afamin levels were positively correlated with metabolic parameters including the body mass index, waist circumference, systolic blood pressure, liver enzymes, and lipid profiles. A multiple regression analysis showed that serum afamin levels were independently related to the risk of NAFLD (OR: 1.289, 95% CI, 1.141–1.456; ). The receiver operating characteristic (ROC) analysis showed that the area under curve (AUC) of serum afamin plus the BMI for detecting NAFLD was 0.878. In participants with liver biopsies, the serum afamin plus the BMI detected NAFLD with an AUC of 0.758. In conclusion, serum afamin levels were positively associated with prevalence and risk of NAFLD, and serum afamin plus the BMI had a high diagnostic performance for NAFLD. This study provides epidemiological evidence of afamin in NAFLD.
- Open Access
- 30 August 2021
- Published by Springer Nature in Environmental Health
- Vol. 20 (1) , 1-11
Associations of acrylamide with non-alcoholic fatty liver disease in American adults: a nationwide cross-sectional study
Background: Acrylamide (AA) is a toxicant to humans, but the association between AA exposure and the risk of non-alcoholic fatty liver disease (NAFLD) remains unclear. In this study, our objective is to examine the cross-sectional association between AA exposure and the risk of NAFLD in American adults. Methods: A total of 3234 individuals who took part in the National Health and Nutrition Examination Survey (NHANES) 2003–2006 and 2013–2016 were enrolled in the study. NAFLD was diagnosed by the U.S. Fatty Liver Index. Multivariable logistic regression models were applied to estimate the association between AA and NAFLD in the whole group and the non-smoking group. Results: We discovered that in the whole group, serum hemoglobin adducts of AA (HbAA) were negatively associated with the prevalence of NAFLD after adjustment for various covariables (P for trend < 0.001). Compared with individuals in the lowest HbAA quartiles, the odds ratios (ORs) with 95% confidence intervals (CIs) in the highest HbAA quartiles were 0.61 (0.46–0.81) and 0.57 (0.36–0.88) in the whole group and the non-smoking group, respectively. In contrast, HbGA/HbAA showed a significantly positive correlation with the prevalence of NAFLD in both groups (P for trend < 0.001). In addition, HbGA was not significantly associated with NAFLD in the whole group or the non-smoking group. Conclusions: HbAA is negatively associated with NAFLD whereas HbGA/HbAA is positively associated with NAFLD in adults in the U.S. Further studies are needed to clarify these relationships.
- 30 August 2021
- Published by Springer Nature in Environmental Health
- Vol. 20 (1) , 1-11
Open AccessAssociations of acrylamide with non-alcoholic fatty liver disease in American adults: a nationwide cross-sectional study
Background: Acrylamide (AA) is a toxicant to humans, but the association between AA exposure and the risk of non-alcoholic fatty liver disease (NAFLD) remains unclear. In this study, our objective is to examine the cross-sectional association between AA exposure and the risk of NAFLD in American adults. Methods: A total of 3234 individuals who took part in the National Health and Nutrition Examination Survey (NHANES) 2003–2006 and 2013–2016 were enrolled in the study. NAFLD was diagnosed by the U.S. Fatty Liver Index. Multivariable logistic regression models were applied to estimate the association between AA and NAFLD in the whole group and the non-smoking group. Results: We discovered that in the whole group, serum hemoglobin adducts of AA (HbAA) were negatively associated with the prevalence of NAFLD after adjustment for various covariables (P for trend < 0.001). Compared with individuals in the lowest HbAA quartiles, the odds ratios (ORs) with 95% confidence intervals (CIs) in the highest HbAA quartiles were 0.61 (0.46–0.81) and 0.57 (0.36–0.88) in the whole group and the non-smoking group, respectively. In contrast, HbGA/HbAA showed a significantly positive correlation with the prevalence of NAFLD in both groups (P for trend < 0.001). In addition, HbGA was not significantly associated with NAFLD in the whole group or the non-smoking group. Conclusions: HbAA is negatively associated with NAFLD whereas HbGA/HbAA is positively associated with NAFLD in adults in the U.S. Further studies are needed to clarify these relationships.